Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.66 |
| ▸ | CES2 | O00748 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7852918 | 1.00 | CES1 (0.66) | CES1CES2TDP1POLBMAPK1 | |
| SCHEMBL7842426 | 1.00 | CES1 (0.66) | CES1CES2TDP1POLBMAPK1 | |
| SCHEMBL15515489 | 0.87 | CES1 (0.62) | CES1CES2TDP1POLBMAPK1 | |
| SCHEMBL11224077 | 0.87 | CES1 (0.62) | CES1CES2TDP1POLBMAPK1 | |
| SCHEMBL11224088 | 0.87 | CES1 (0.62) | CES1CES2TDP1POLBMAPK1 | |
| SCHEMBL8134880 | 0.85 | TP53 (0.63) | CES1CES2MAOBMEN1KMT2A | |
| SCHEMBL7063316 | 0.85 | TP53 (0.63) | CES1CES2MAOBMEN1KMT2A | |
| SCHEMBL7063319 | 0.85 | TP53 (0.63) | CES1CES2MAOBMEN1KMT2A | |
| SCHEMBL4333511 | 0.84 | RAB9A (0.53) | CES1CES2TDP1POLBMAPK1 | |
| SCHEMBL7783945 | 0.81 | TP53 (0.67) | CES1CES2MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0790998-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-08-27 | — | — | EP | claimed |
| WO-1997009329-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-03-13 | — | — | WO | claimed |
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| WO-2014031755-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2310371-B1 | PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA | GENFIT (FR) | 2013-05-15 | — | — | EP | disclosed |
| EP-0790998-B1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | URIACH & CIA SA J (ES) | 2001-01-17 | — | — | EP | disclosed |
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | disclosed |
| US-5747477-A | INFLAMMATORY BOWEL DISEASE, GASTROINTESTINAL DISORDERS, CROHN*S DISEASE | J. URIACH & CIA S.A. (ES) | 1998-05-05 | — | — | US | disclosed |
| US-5705504-A | PLATELET ACTIVATING FACTOR | J. URIACH & CIA, S.A. (ES) | 1998-01-06 | — | — | US | disclosed |
| EP-0790998-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997009329-A1 | AZO DERIVATIVES OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | J. URIACH & CIA. S.A. (ES) | 1997-03-13 | — | — | WO | disclosed |
| EP-0738269-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996014317-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | KRAS, RASSF5, RASSF2 | CES1 344/4885CES2 1093/4885TDP1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.